Primmune Therapeutics - About the company
Primmune Therapeutics is a series B company based in San Diego (United States), founded in 2017 by Paulo Rangel. It operates as a Developer of immunotherapies for treating cancer. Primmune Therapeutics has raised $60M in funding from investors like CAM Capital, Polaris Partners and Bioqube Ventures. The company has 354 active competitors, including 134 funded and 68 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.
Company Details
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
- Website
- www.primmunerx.com/
- Social
- Email ID
- *****@primmunerx.com
Key Metrics
Founded Year
2017
Location
San Diego, United States
Stage
Series B
Total Funding
$60M in 8 rounds
Latest Funding Round
Investors
Ranked
12th among 354 active competitors
Employee Count
10 as on Sep 30, 2026
Similar Companies
Sign up to download Primmune Therapeutics' company profile
Primmune Therapeutics's funding and investors
Primmune Therapeutics has raised a total funding of $60M over 8 rounds. Its first funding round was on Oct 18, 2017. Its latest funding round was a Series B round on Jan 26, 2026 for $*****. 3 investors participated in its latest round. Primmune Therapeutics has 9 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Primmune Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 26, 2026 | 7179355 | Series B | 1581199 | 7656020 | 8205936 | 9423818 |
Nov 04, 2021 | 4593393 | Series A | 3345332 | 1692184 | 6530892 | 6508351 |
Jan 12, 2021 | 6693963 | Series A | 5396235 | 4178070 | 1062155 |
Access funding benchmarks and valuations. Sign up today!View details of Primmune Therapeutics's funding rounds and investors
Primmune Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Primmune Therapeutics is Paulo Rangel. Charles Charlie Mcdermott is the CEO of Primmune Therapeutics.
Here are the details of Primmune Therapeutics' key team members:
- Paulo Rangel: Co-Founder & CBO of Primmune Therapeutics. Contact Info: 1 email address
View details of Primmune Therapeutics's Founder profiles and Board Members
Primmune Therapeutics' employee count trend
Primmune Therapeutics has 10 employees as of Sep 26. Here is Primmune Therapeutics's employee count trend over the years:
Uncover Primmune Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Primmune Therapeutics's Competitors and alternates
Top competitors of Primmune Therapeutics include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Primmune Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
2nd | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
3rd | _1556184640480.png?devicePixelRatio=2&height=30&width=30){kind=logo} TScan Therapeutics 1995, Boston (United States), Public | Developer of T cell therapies to harness the immune system against cancer | $180M | 70/100 | |
4th | _1548143983431.png?devicePixelRatio=2&height=30&width=30){kind=logo} Beijing Jiakesi drug development 2015, Beijing (China), Public | Developer of small molecule based therapeutics for cancer treatment | $55M | 67/100 | |
5th | Lyell Immunopharma 2018, San Francisco (United States), Public | Developer of CAR- T therapy for cancer treatment | $493M | 63/100 | |
6th | ABL Bio 2016, Seongnam-si (South Korea), Public | Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 63/100 | |
7th | Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed | Developer of therapies for treating cancers | $19.2M | 61/100 | |
8th |  Black Diamond Therapeutics 2017, Cambridge (United States), Public | Developing MasterKey therapies to defeat cancer resistance and improve patient lives | $207M | 61/100 | |
9th | _1568982092325.png?devicePixelRatio=2&height=30&width=30){kind=logo} Boundless Bio 2018, San Diego (United States), Public | Developer of therapeutics for cancer by targeting ecDNA | $252M | 61/100 | |
10th | FoRx Therapeutics 2019, Basel (Switzerland), Series A | Developer of compounds for treating cancer | $60.8M | 60/100 | |
12th | Primmune Therapeutics 2017, San Diego (United States), Series B | Developer of immunotherapies for treating cancer | $60M | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Primmune Therapeutics's competitors? Click here to see the top ones
Primmune Therapeutics's Investments and acquisitions
Primmune Therapeutics has made no investments or acquisitions yet.
Reports related to Primmune Therapeutics
Here is the latest report on Primmune Therapeutics's sector:
News related to Primmune Therapeutics
Filter this listMedia has covered Primmune Therapeutics for 1 event in last 1 year.
•
Primmune Therapeutics Announces Additional Close of Series B FinancingBenzinga•Jan 26, 2026•Primmune Therapeutics, Samsara BioCapital, Oberland Capital, Bioqube Ventures
•
Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa FeverBakersfield•Mar 20, 2024•Primmune Therapeutics, Defense Threat Reduction Agency
•
Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual MeetingBusiness Wire•Nov 10, 2023•Primmune Therapeutics
•
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual MeetingTullahoma News•Oct 11, 2023•Primmune Therapeutics
•
Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual MeetingBusiness Wire•Apr 18, 2023•Primmune Therapeutics
•
Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual MeetingBusiness Wire•Mar 28, 2022•Primmune Therapeutics
•
Primmune Therapeutics Presents Interim Analysis Of Clinical Data From Phase 1 Study Evaluating Prtx007 At The Conference On Retroviruses And Opportunistic InfectionsPipelinereview•Feb 14, 2022•Primmune Therapeutics
•
Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A FinancingBusiness Wire•Nov 04, 2021•Primmune Therapeutics
•
Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™Business Wire•Nov 02, 2021•Primmune Therapeutics
•
Primmune Therapeutics Strengthens Leadership Team with Key AppointmentsBusiness Wire•Feb 05, 2021•Primmune Therapeutics, Intercept Pharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Primmune Therapeutics
Explore our recently published companies
- Futterhandel Grotenburg - Willich based, Unfunded company
- Real Office - India based, Unfunded company
- Talking Cherry - Tokyo based, 2016 founded, Unfunded company
- Franchise Guides - Unfunded company
- Head Start School - Karachi based, 1992 founded, Unfunded company
- Vapl - India based, 2025 founded, Unfunded company
